MedTrace Logo

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2026-04-29

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Conditions

Interventions

DRUG

Cevostamab

Participants will receive cevostamab IV as per the schedule given in the protocol.

DRUG

Pomalidomide

Participants will receive pomalidomide tablet orally PO as per the schedule given in the protocol.

DRUG

Dexamethasone

Participants will receive dexamethasone tablet orally PO or IV as per the schedule given in the protocol.

DRUG

Daratumumab

Participants will receive daratumumab SC as per the schedule given in the protocol.

DRUG

Elotuzumab

Participants will receive elotuzumab IV as per the schedule given in the protocol.

DRUG

Carfilzomib

Participants will receive carfilzomib IV as per the schedule given in the protocol.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2029-06-29
Completion
2032-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07555938 on ClinicalTrials.gov